Literature DB >> 23486263

Taking aim at ALK across the blood-brain barrier.

D Ross Camidge.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23486263     DOI： 10.1097/JTO.0b013e3182864e7c

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  15 in total

Review 1.  Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Authors:  Ryohei Katayama; Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

Review 2.  Tackling ALK in non-small cell lung cancer: the role of novel inhibitors.

Authors:  Francesco Facchinetti; Marcello Tiseo; Massimo Di Maio; Paolo Graziano; Emilio Bria; Giulio Rossi; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2016-06

Review 3.  Novel agents in development for advanced non-small cell lung cancer.

Authors:  Thomas E Stinchcombe
Journal:  Ther Adv Med Oncol       Date:  2014-09       Impact factor: 8.168

4.  Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.

Authors:  Daniel B Costa; Alice T Shaw; Sai-Hong I Ou; Benjamin J Solomon; Gregory J Riely; Myung-Ju Ahn; Caicun Zhou; S Martin Shreeve; Paulina Selaru; Anna Polli; Patrick Schnell; Keith D Wilner; Robin Wiltshire; D Ross Camidge; Lucio Crinò
Journal:  J Clin Oncol       Date:  2015-01-26       Impact factor: 44.544

5.  PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.

Authors:  Helen Y Zou; Luc Friboulet; David P Kodack; Lars D Engstrom; Qiuhua Li; Melissa West; Ruth W Tang; Hui Wang; Konstantinos Tsaparikos; Jinwei Wang; Sergei Timofeevski; Ryohei Katayama; Dac M Dinh; Hieu Lam; Justine L Lam; Shinji Yamazaki; Wenyue Hu; Bhushankumar Patel; Divya Bezwada; Rosa L Frias; Eugene Lifshits; Sidra Mahmood; Justin F Gainor; Timothy Affolter; Patrick B Lappin; Hovhannes Gukasyan; Nathan Lee; Shibing Deng; Rakesh K Jain; Ted W Johnson; Alice T Shaw; Valeria R Fantin; Tod Smeal
Journal:  Cancer Cell       Date:  2015-07-02       Impact factor: 31.743

6.  A real-world study of treatment patterns and survival outcome in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer.

Authors:  Ying Jin; Yamei Chen; Xinmin Yu; Xun Shi
Journal:  Oncol Lett       Date:  2018-04-05       Impact factor: 2.967

7.  PROFILE 1014: lessons for the new era of lung cancer clinical research.

Authors:  Sinead A Noonan; D Ross Camidge
Journal:  Transl Lung Cancer Res       Date:  2015-10

Review 8.  Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors:  D Ross Camidge; William Pao; Lecia V Sequist
Journal:  Nat Rev Clin Oncol       Date:  2014-07-01       Impact factor: 66.675

9.  Editorial on the article entitled "brigatinib efficacy and safety in patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer in a phase I/II trial".

Authors:  Ivana Sullivan; David Planchard
Journal:  J Thorac Dis       Date:  2016-10       Impact factor: 2.895

Review 10.  Updates in the management of brain metastases.

Authors:  Nils D Arvold; Eudocia Q Lee; Minesh P Mehta; Kim Margolin; Brian M Alexander; Nancy U Lin; Carey K Anders; Riccardo Soffietti; D Ross Camidge; Michael A Vogelbaum; Ian F Dunn; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2016-08       Impact factor: 12.300
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.